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Abstract 91 
Restrictive cardiomyopathies are a diverse group of myocardial diseases with a wide range 92 
of aetiologies, including familial, genetic and acquired diseases and ranging from very rare 93 
to relatively frequent cardiac disorders. In all these diseases, imaging techniques play a 94 
central role. Advanced imaging techniques provide important novel data on the diagnostic 95 
and prognostic assessment of restrictive cardiomyopathies. This EACVI consensus 96 
document provides comprehensive information for the appropriateness of all non-invasive 97 
imaging techniques for the diagnosis, prognostic evaluation, and management of patients 98 
with RCM.  99 
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1. Introduction  143 
Restrictive cardiomyopathies (RCM) are a diverse group of myocardial diseases with a wide 144 
range of aetiologies, including familial, genetic and acquired diseases and ranging from very 145 
rare to relatively frequent cardiac disorders. This diversity is also reflected in the 146 
inconsistent classification of RCM across guidelines (1-3) and even in the term “restrictive”, 147 
which is a functional characterization, unlike the morphological definition of the three other 148 
main types of cardiomyopathies, i.e. hypertrophic, arrhythmogenic right ventricular or 149 
dilated cardiomyopathies (4).  150 
Independently of the underlying cause, the pathophysiology and clinical presentation, the 151 
initial phenotypic diagnosis of RCM requires imaging techniques. Many advances have 152 
occurred in the last decade in the diagnostic and prognostic assessment of RCM. This EACVI 153 
consensus document provides comprehensive information for the appropriateness of all 154 
non-invasive imaging techniques for the diagnosis, prognostic evaluation, and management 155 
of patients with RCM.  156 
This article was written in close collaboration between the European Association of 157 
Cardiovascular Imaging (EACVI) and the Working Group (WG) on Myocardial and Pericardial 158 
diseases of the European Society of Cardiology (ESC). The types of RCM covered in this 159 
document are those included in the classification system proposed by the WG on Myocardial 160 
and Pericardial diseases (1) as well as some non-sarcomeric hypertrophic cardiomyopathies 161 
with a restrictive physiology that in previous classifications were included in the RCM 162 
category, e.g. cardiac amyloidosis. 163 
 164 
2. Definition and classification of RCM  165 
RCM is the least common type of the cardiomyopathies, defined as myocardial disorders in 166 
which the heart muscle is structurally and functionally abnormal in the absence of coronary 167 
artery disease, arterial systemic hypertension, valvular disease or congenital heart disease 168 
sufficient to cause the observed myocardial abnormality (1). 169 
According to the historical World Health Organization (WHO) (2) and the updated definition 170 
proposed by the ESC WG on Myocardial and Pericardial Diseases in 2008 (1), each 171 
cardiomyopathy type is described by its clinical presentation. This approach is 172 
recommended firstly because it is the starting point in everyday clinical practice, and 173 
secondly because knowledge of aetiologies is still evolving, thus at present an aetiological 174 
classification would not be conclusive. 175 
RCM is defined by restrictive ventricular physiology in the presence of normal or reduced 176 
diastolic volumes, with normal or near-normal left ventricular (LV) systolic function, and 177 
normal or near-normal wall thickness (1-5). Increased interstitial fibrosis may be present. 178 
RCM constitutes a heterogeneous group of heart muscle diseases with various causes (Table 179 
1) that may be classified according to very different criteria.  180 
According to the main pathophysiological mechanism, RCM may be subclassified into 181 
infiltrative or storage diseases (e.g. amyloidosis and glycogen storage disease); obliterative 182 
or endomyocardial diseases (e.g. endomyocardial fibrosis, related or not to 183 
hypereosinophilia). 184 
The WHO classification system was based on the distinction between primary and secondary 185 
myocardial disorders (2). Primary cardiomyopathies were defined as either not caused by an 186 
identifiable agent, e.g. idiopathic, or related to a primary myocardial cause. Secondary 187 
diseases were related to systemic disorders affecting the myocardium with a 188 
pathophysiological process starting outside of, e.g. unspecific to the myocardium. The 189 
American Heart Association (AHA) proposed a slightly different classification system in 190 
which the term “primary” was used to describe diseases in which the heart is the sole or 191 
predominantly involved organ whereas “secondary” is used to describe diseases in which 192 
myocardial dysfunction is part of a systemic disorder (3).  193 
However, the challenge of distinguishing primary and secondary disorders is illustrated by 194 
the fact that many diseases classified as primary cardiomyopathies (e.g. glycogen storage 195 
disease, mitochondrial cytopathies) in the AHA classification can be associated with major 196 
extra-cardiac manifestations. Conversely, pathology in many of the diseases classified as 197 
secondary cardiomyopathies can predominantly (or exclusively) involve the heart (e.g. 198 
endomyocardial fibrosis or Fabry disease cardiac variant). In addition, the term of primary 199 
cardiomyopathy as an idiopathic condition is no longer appropriate in a large group of 200 
patients since genetics has identified mutations in various genes such as sarcomeric causes. 201 
Therefore, the ESC WG on Myocardial & Pericardial Diseases proposed in 2008 to abandon 202 
the distinction between primary and secondary causes (1). 203 
As an alternative to this classification, the ESC Working Group on Myocardial and 204 
Pericardial Diseases proposed to subclassify RCM and other cardiomyopathies into (i) 205 
familial or genetic causes and (ii) non-familial/non-genetic causes, because of the recent 206 
and increasing knowledge about genetic causes of cardiomyopathies. This is especially 207 
illustrated in RCM related to cardiac amyloidosis that may be acquired (amyloidosis AL or 208 
senile amyloidosis) or genetically determined (transthyretin and other genes mutations) and 209 
be included in the nonsarcomeric hypertrophic cardiomyopathies as well as in the RCM (1). 210 
The latter ESC classification will be used in this position paper. 211 
 212 
3. Pathophysiology of RCM and clinical presentation  213 
Restrictive physiology is characterized by a pattern of LV filling in which increased stiffness 214 
of the myocardium causes a precipitously rise of LV pressure with only small increases in 215 
volume. On cardiac catheterization, this phenomenon is characterized by a dip-and-plateau 216 
contour of early diastolic pressure traces. The standard echocardiographic features of 217 
‘restrictive’ filling are described in chapter 4.1 218 
Similarly, Some patients with a restrictive physiology may have significantly increased wall 219 
thickness such as patients with cardiac amyloidosis. RCM should be differentiated from 220 
constrictive pericarditis (6, 7). (see chapter 5). 221 
 222 
4. Imaging modalities in RCM:  223 
1 - Echocardiography  224 
Echocardiography plays a key role for the recognition of RCM. The echocardiographic 225 
diagnosis requires to differentiate RCM from constrictive pericarditis. 226 
RCM are usually characterized by normal or small LV cavity size (< 40mL/m2) with preserved 227 
LV ejection fraction, bi-atrial enlargement, and diastolic dysfunction (5).  228 
Assessment of LV diastolic function and filling pressures is of utmost value in RCM. In the 229 
recent joint American Society of Echocardiography (ASE) / EACVI recommendations for the 230 
evaluation of diastolic function by echocardiography (8), the four recommended variables to 231 
diagnose LV diastolic dysfunction and their abnormal cut-off values are annular e’ velocity 232 
(septal e’ <7 cm/s, lateral e’ <10 cm/s), average E/e’ ratio >14, LA maximum volume index 233 
>34 ml/m2, and peak TR velocity >2.8 m/s (figure 1). Other valuable parameters to identify 234 
the presence of elevated LV filling pressures are the ratio of pulmonary vein peak systolic to 235 
peak diastolic velocity, or systolic time velocity integral to diastolic time velocity integral <1, 236 
and the changes in E/A ratio with Valsalva manoeuver. The restrictive filling is considered 237 
reversible if the change of E/A ratio during Valsalva is ≥0.5 and fixed if it is <0.5 (more 238 
severe form).  239 
The diagnosis of RCM does not equal the presence of restrictive physiology. Patients with 240 
true RCM may present with a grade I diastolic dysfunction and move progressively to grade 241 
II or III diastolic dysfunction, with worsening of their disease. The advanced stages of RCM 242 
are characterized by typical restrictive physiology with a mitral inflow E/A ratio > 2.5, DT 243 
of E velocity <150 ms, IVRT < 50 ms, decreased septal and lateral e’ velocities ( 3-4 cm/s), 244 
E/e’ ratio > 14, as well as a markedly  increased LA volume index (> 50 ml/m2)(8), this 245 
advanced restrictive pattern being associated with the worst prognosis (9). Wall thickness 246 
is usually normal.  247 
Some specific features may also help differentiate secondary RCM, including several 248 
systemic conditions (diabetic cardiomyopathy, scleroderma, endomyocardial fibrosis, 249 
radiation, chemotherapy, carcinoid heart disease, metastatic cancers), from apparently 250 
idiopathic RCM (see chapter 5).  Ultrasonic tissue characterisation with integrated 251 
backscatter has been used to assess myocardial texture, but is non-specific (10, 11). Finally, 252 
2D deformation imaging is useful for the assessment of LV longitudinal dysfunction, which 253 
is frequently impaired in most forms of RCM (12) (see chapter 5), and may help 254 
differentiating RCM form constrictive pericarditis (13) 255 
 256 
2 - Cardiovascular magnetic resonance (CMR) 257 
CMR imaging can contribute importantly to the diagnosis of RCM and the differential 258 
diagnosis from pericardial constriction [14]. The CMR methods most commonly used for the 259 
assessment of RCM include static (black blood) images, cine and contrast enhanced imaging 260 
as well as parametric mapping.  261 
Static images are used to delineate cardiac, pericardial and vascular morphology. T1 and 262 
T2 weighted black blood images are sensitive to different tissue characteristics and provide 263 
complementary information. T1 weighted images show high signal from fat, as may for 264 
example be seen in Fabry’s disease, while T2 weighted short tau inversion recovery (STIR) 265 
images show high signal in myocardial oedema, for example in acute sarcoidosis. 266 
CMR allows accurate volumetric assessment of the heart and can accurately measure 267 
chamber size and function [15].  Typical cine CMR images are averaged over several heart 268 
beats to maximize image quality and temporal resolution, but real-time imaging can also be 269 
performed to demonstrate the typical septal shift during respiratory maneuvers and identify 270 
restrictive physiology [16]. Velocity encoded CMR in standardized imaging planes 271 
perpendicular to the atrio-ventricular heart valves is used to demonstrate the typical 272 
restrictive filling patterns of accentuated early filling and absent or reduced late filling [17].  273 
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A unique feature of CMR of relevance to the imaging of RCM is tissue characterization with 274 
late gadolinium enhancement (LGE). Following intravenous administration gadolinium 275 
based contrast agents are retained preferentially in tissues with an expanded extracellular 276 
space, such as fibrosis, scar or infiltration. Characteristic patterns of contrast enhancement 277 
can be observed in several of the RCMs, contributing to the differential diagnosis of Fabry 278 
disease, amyloidosis, endomyocardial fibrosis and sarcoidosis (Figure 2). In many of these 279 
conditions, the presence of LGE also has important prognostic relevance [18-20]. Finally, 280 
parametric mapping methods have increasing applications in RCM and allow quantitative 281 
measurement of tissue characteristics. T2*-weighted CMR is now the method of choice to 282 
detect and quantify myocardial iron content in iron deposition cardiomyopathy and to guide 283 
appropriate therapy [21]. A low myocardial T2* value in this context is currently considered 284 
the most powerful marker of adverse outcome [22]. More recently, T1 mapping has been 285 
used to quantify the extent of myocardial inflammation and fibrosis. Native T1 relaxation 286 
times, as measured with T1 mapping without the need for contrast agent administration, 287 
are altered in several conditions including amyloidosis and may have incremental value over 288 
LGE imaging [23]. The combination of native and post contrast T1 mapping allows an 289 
estimation of the myocardial extracellular volume (ECV) fraction, which in amyloidosis can 290 
even show differences in subtypes of the disease [24]. T1 mapping may also be useful in 291 
iron overload instead of the more established T2* mapping [25]. 292 
 293 
3 - Cardiac computed tomography (CT) 294 
The key advantage of computed tomography (CT) is its high-spatial resolution and the 295 
anatomical detail it provides. However the associated radiation exposure largely limits this 296 
modality to static imaging, precluding dynamic analyses of left ventricular haemodynamics, 297 
filling or relaxation. Nevertheless CT is well suited to identifying the anatomic features of 298 
impaired cardiac filling that characterize RCM. These include dilatation of the atria, 299 
coronary sinus and inferior vena cava and the presence of pulmonary congestion and pleural 300 
effusions. These features are also observed in a range of other conditions and the 301 
predominant role of CT with respect to RCM is in the exclusion of these alternative 302 
diagnoses. In particular, CT is well suited to detecting the thickening and calcification of 303 
the pericardium most commonly associated with constrictive pericarditis (26). Similarly CT 304 
allows assessment of extra-cardiac involvement in systemic conditions such as sarcoidosis 305 
(e.g. pulmonary nodules, pulmonary fibrosis and lymphadenopathy) or amyloidosis (e.g. 306 
inhomogeneous hepatomegaly, diffuse lung parenchymal involvement, small kidneys) 307 
further aiding in the differential diagnosis.  308 
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When other imaging modalities are not available, CT may be useful in evaluation of patients 309 
with RCM, owing to its ability to measure LV wall thickness and mass, detect regional wall 310 
thickening (27), regions of replacement fibrosis (27, 28), and measure myocardial 311 
extracellular volume fraction by equilibrium contrast-enhanced CT to assess diffuse fibrosis 312 
(29). These advances may increase the clinical utility of CT in the future clinical assessment 313 
of patients with RCM, particularly when echocardiography and CMR are non-diagnostic or 314 
contraindicated. 315 
 316 
4 – Nuclear imaging 317 
Nuclear imaging modalities have a potential clinical role in two forms of RCM: amyloidosis 318 
and sarcoidosis (see chapters 5.2 and 5.4). Nuclear imaging modalities have the advantage 319 
of specific targeted molecular imaging. Positron emission tomography (PET) has the 320 
technical advantages of high spatial resolution, robust built-in attenuation correction, 321 
quantitative analysis, and low patient radiation exposure, whereas single photon emission 322 
computed tomography (SPECT) has the advantage of a robust, cheaper and well validated 323 
camera system 324 
There are increasing data on the role of nuclear tracers with SPECT and more recently with 325 
PET for early identification and differential diagnosis of cardiac amyloidosis, particularly 326 
transthyretin-related amyloidosis (ATTR) 327 
Radiolabelled SPECT phosphate derivatives, initially developed as bone-seeking tracers, 328 
were noted to localize to amyloid deposits using [99mTc]-diphosphanate (30). In clinical 329 
practice, the most used SPECT tracers are: 99mTc-DPD mainly in Europe and Asia and 330 
99mTc-PYP in the United States. Their main advantage is avid uptake by ATTR and minimal 331 
uptake with the light-chain (AL) amyloidosis subtype, providing one of the best non-invasive 332 
ways to differentiate these subtypes of cardiac amyloidosis. (31, 32) 333 
The imaging technique is simple. Briefly, after administering 740 MBq of 99mTc-DPD, or or 334 
[99mTc]-HDP (32, 33), or of 99mTc-PYP (34) intravenously, a whole-body scan is performed 335 
3 hours or 1 h later (anterior and posterior projections). If there is active uptake in the heart, 336 
chest SPECT is performed. The analysis is performed by semi-quantitative visual scoring of 337 
the cardiac as compared to the bone uptake (scores from 0 to 3) and by computing the ratio, 338 
after correction for background counts, of the mean counts in the heart region over the 339 
mean counts in the contralateral chest ( H/CL ratio). 340 
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Other nuclear imaging approaches have been recently proposed for the diagnosis and 341 
prognostic stratification of patients with suspected amyloidosis. (31) PET imaging using new 342 
amyloid tracers like the [11C]-labeled Pittsburgh Compound B (PiB) or [18F]-florbetapir is 343 
promising and under early clinical investigation. The use of neuronal imaging by [123-I]-344 
MIBG SPECT has been suggested for early recognition of cardiac involvement and prognostic 345 
stratification of individuals with TTR mutation (34) 346 
The inflammatory nature of cardiac sarcoidosis renders PET useful for its diagnosis, as 347 
[18F]FDG accumulates in inflammatory cells in the heart. FDG is preferred in combination 348 
with a perfusion tracer to improve specificity, due to better match/mismatch pattern 349 
recognition. Unlike in CMR, there is no distinct pattern of FDG uptake that is 350 
pathognomonic for cardiac sarcoidosis, though focal or focal on diffuse uptake is suggestive 351 
of the disorder.(35) At present, [18F]FDG-PET appears to be more sensitive but less specific 352 
than CMR (36) and its use seems most appropriate in patients who have contraindications 353 
to CMR, inconclusive findings on CMR or where CMR is not available also to monitor 354 
response to therapy. The development of FDG PET/MR techniques offers the ability to 355 
assess LV wall function, the pattern of myocardial injury and disease activity in a single 356 
scan (37) (figure 3 ) 357 
 358 
In summary, several imaging techniques are available in the evaluation of RCM, all of which 359 
have both advantages and limitations. Table 2 summarizes the value of different imaging 360 
modalities in various forms of RCM. Although non-invasive techniques are sufficient in most 361 
cases, final histologic diagnosis may sometimes be necessary, and may be obtained by 362 
biopsies specimens from the heart (endomyocardial biopsies [EMB]) or other organs. Figure 4 363 
illustrates by histology and immunohistology different disease entities of RCM which will be 364 
discussed in the following chapters. 365 
 366 
 367 
 368 
 369 
 370 
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5. Main forms of RCM and value of imaging techniques: 371 
1 – Apparently idiopathic RCM 372 
Apparently idiopathic RCM may be caused by mutations in sarcomeric disease genes and 373 
may even coexist with hypertrophic cardiomyopathy in the same family (38-40) and may 374 
require EMB (to exclude cardiac amyloidosis), family screening and genetic investigations. 375 
Most affected individuals have severe signs and symptoms of heart failure. Several studies 376 
have reported that 66–100% die or receive a cardiac transplant within a few years of 377 
diagnosis. 378 
The echocardiographic diagnosis is one of restrictive physiology and mostly preserved LV 379 
ejection fraction. Typically, idiopathic RCM is characterised by diastolic dysfunction with 380 
apparently preserved systolic function, dilated atria, and the absence of ventricular 381 
hypertrophy or dilatation (figure 5 and videos 1 and 2). Longitudinal function may be 382 
decreased; the right ventricle may be involved but there is no “pathognomonic” 383 
echocardiographic pattern of apparently idiopathic RCM. CMR with LGE may facilitate the 384 
diagnosis of infiltrative myocardial disease, and is thus particularly useful for ruling out a 385 
particular cause of RCM (41).  386 
 387 
2 – Cardiac amyloidosis  388 
Cardiac amyloidosis (CA) is one of the most frequent causes of RCM and may be 389 
genetic/familial (ATTR) or non-genetic non-familial (AL/ prealbumin, senile).  390 
The diagnosis requires awareness, expertise and a high level of clinical suspicion, with 391 
integration between clinical, electrocardiographic and echocardiographic data. The 392 
“mismatch” between the presence of LV hypertrophy (LVH) in echocardiography and its 393 
absence on the ECG (no LVH, absolute or relative low-voltage QRS) is suggestive of cardiac 394 
amyloidosis and is often the first disease “red flag” (42, 43). Typical echocardiographic 395 
findings in cardiac amyloidosis patients include (figure 6a) a non-dilated LV with moderate 396 
concentric LVH and a ‘granular sparkling’ appearance of the myocardial texture, valvular 397 
thickening (mainly the A-V valves), biatrial dilatation, right ventricular free wall 398 
hypertrophy, inter atrial septum infiltration (loss of physiological echo drop-out) and mild 399 
pericardial effusion (44). In the early stages of the disease, cardiac amyloidosis may present 400 
as asymmetrical septal hypertrophy, sometimes with LV outflow tract obstruction and can 401 
then be wrongly diagnosed as hypertrophic cardiomyopathy (HCM). The presence of intra-402 
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atrial thrombus also seems to be relatively frequent in patients with cardiac amyloidosis, 403 
even in sinus rhythm (45). 404 
Patients often show (figure 6b) advanced diastolic dysfunction (grade II or III) and increased 405 
LV filling pressures. The classical transmitral restrictive pattern may only be seen at 406 
advanced disease stages. The typical tissue Doppler imaging (TDI) pattern of cardiac 407 
amyloidosis, with low systolic (s’) and diastolic  (e’, a’) myocardial velocities. Of note, E/e’ 408 
ratio is usually abnormally increased even in the presence of LV abnormal relaxation pattern 409 
(diastolic dysfunction grade I) (46). 410 
 LV systolic dysfunction is also a common finding in this disease. In early stages, despite 411 
preserved LV ejection fraction, longitudinal function is abnormal (abnormal long axis 412 
systolic velocities (s’) and strain) (figure 7a) as well as myocardial contraction fraction, a 413 
recently described systolic parameter (47).  414 
2D speckle-tracing echocardiography (2D-STE) is important, as many systolic strain 415 
parameters (longitudinal, circumferential, radial) are abnormal in cardiac amyloidosis, 416 
particularly in the longitudinal axis, typically with prominent involvement of LV basal 417 
segments and apical sparing (48) (figure 7b), reflecting the predominant deposition of 418 
amyloid in basal segments. The combination of a prominent reduction of longitudinal strain 419 
in LV basal segments with increased E/e’ ratio suggests cardiac amyloidosis in early stages 420 
(49).  421 
Multiple echocardiographic parameters have been associated with adverse outcomes in 422 
cardiac amyloidosis, including M- mode and 2D data (maximal wall thickness, LV fractional 423 
shortening and LV ejection fraction, right ventricle dilatation), blood pool Doppler data 424 
(restrictive filling pattern, myocardial performance index, Tissue Doppler derived data 425 
(myocardial velocities, long axis velocity gradient, peak  longitudinal systolic basal antero-426 
septal strain > -7.5%) (50) and 2D-STE parameters (GLS, mid-septum systolic longitudinal 427 
strain, apical LS< -14.5%) (51, 52).  428 
CMR is often used after CA is suspected by echocardiography to confirm or refute the 429 
diagnosis, and in experienced hands represents a powerful tool with important diagnostic 430 
and prognostic implications. Cine images may demonstrate typical anatomical features like 431 
thickened LV wall, biatrial enlargement, reduced long-axis shortening, and pleural or 432 
pericardial effusion. The presence of amyloid protein in the myocardial interstitium is 433 
associated with abnormal gadolinium-chelate contrast kinetics and characteristic patterns 434 
of contrast distribution. LGE images typically show circumferential subendocardial contrast 435 
enhancement or bilateral septal subendocardial LGE with dark mid-wall (zebra pattern) 436 
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(Figure 8a) (53, 54), but other patterns of enhancement have also been described. In atypical 437 
cases, other differential diagnoses should be considered such as hypertrophic 438 
cardiomyopathy or Fabry’s disease. Cardiac involvement can extend to the right ventricle 439 
and atrial walls, as potentially detected by LGE. The extent of myocardial LGE correlates 440 
with New York Heart Association functional class, LV wall thickness, lower ECG voltage, 441 
and cardiac biomarkers (troponins, brain natriuretic peptide)(55). With more advanced 442 
disease, amyloid infiltration may be transmural with corresponding global enhancement on 443 
LGE images, which is an independent predictor of poorer outcomes, over stroke volume and 444 
pro-NT brain natriuretic peptide. (56)  445 
 Amyloid deposits increase the longitudinal relaxation time (T1) magnetic property of 446 
the heart. Thus, myocardial non-contrast T1 values are longer in cardiac amyloidosis than 447 
in controls, a finding with higher sensitivity for detecting early subclinical cardiac 448 
involvement than LGE.(57) ECV estimation from pre- and post-contrast T1 mapping has 449 
been used to quantify interstitial amyloid deposition which appears to be more extensive in 450 
transthyretin amyloidosis (TTR) than in immunoglobulin light-chain amyloidosis (AL). (58) 451 
The addition of parametric mapping to standard CMR images is promising to be a powerful 452 
and quantitative diagnostic tool that also allows differential diagnosis from other diseases 453 
with similar phenotypic expression. 454 
Scintigraphy employs molecular-targeted radiolabeled compounds to detect systemic and 455 
organ-specific amyloid deposits. Scintigraphy is a valuable alternative to CMR particularly 456 
for patients with ATTR amyloidosis due to its very high sensitivity. Scintigraphy may also 457 
be used following an inconclusive CMR study, or for phenotyping cardiac amyloidosis (ATTR 458 
vs. AL) or in the differential diagnosis with sarcomeric HCM (59, 60). ). The [99mTc]-labeled 459 
bisphosphonate compounds pyrophosphate (PYP) (60) and 3,3-diphosphono-1,2-460 
propanodicarboxylic acid (DPD)(61) and hydroxydiphosphonate  (HDP) (33) (which are 461 
routinely used as bone scintigraphy agents) bind through unknown mechanisms to amyloid 462 
protein. All have proven very sensitive for detecting cardiac involvement in ATTR amyloidosis 463 
with reported sensitivities up to 100% on late phase planar scintigraphy. Typical uptake 464 
patterns besides cardiac uptake in ATTR amyloidosis include increased soft tissue uptake 465 
(mainly muscular uptake in the gluteal, shoulder, chest and abdominal wall regions) with 466 
obscuring of bone uptake (Figure 8b). However, in AL amyloidosis, cardiac uptake is found 467 
in less than half of patients and is generally less intense (likely due to the lower 468 
concentration of calcium-containing products in AL amyloid). Additionally, AL patients have 469 
generally no muscular [99mTc]-DPD or [99mTc]-HDP uptake while visceral uptake (liver, 470 
spleen) may be more common.  471 
Even if there are not yet large comparative studies, the diagnostic performance of 472 
nuclear imaging for cardiac amyloidosis is established. In general, [99mTc]-DPD can 473 
differentiate subtypes (62) and can be more sensitive than CMR (33) or echocardiography in 474 
diagnosing early disease being an independent prognostic marker (63). In a recent study by 475 
Bokhari et al. (60) using 99mTc-PYP, while patients with AL had some uptake, the visual 476 
score was significantly less than in patients with ATTR, allowing the differentiation between 477 
ATTR and AL amyloidosis with 97% sensitivity and 100% specificity. 478 
Hence, whole body planar DPD and HDP scintigraphy may help to phenotype cardiac 479 
amyloidosis particularly through differentiating ATTR from AL amyloidosis (or from 480 
sarcomeric HCM, where no DPD uptake is seen), which often have overlapping imaging 481 
features on echocardiography and CMR, but very distinct clinical course and prognosis. 482 
Moreover, a recent comparison of [99mTc]-DPD scintigraphy and LGE showed that despite 483 
a general good agreement between both techniques, LGE may sometimes underestimate 484 
cardiac amyloid burden (33). Finally, myocardial tracer uptake on scintigraphy is correlated 485 
with disease severity (measured by circulating troponin and LV wall mass), and has been 486 
shown to be a powerful prognostic determinant of outcome in ATTR cardiac amyloidosis (32, 487 
63).  488 
Recent investigations found that bone scintigraphy enables the diagnosis of cardiac ATTR 489 
amyloidosis to be made reliably without the need for histology in patients who do not have 490 
a monoclonal gammapathy. (64). The algorithm proposed (figure 9) that cardiac ATTR 491 
amyloidosis can be reliably diagnosed in the absence of histology provided an 492 
echocardiogram or CMR is suggestive of amyloidosis, cardiac uptake is present on 493 
scintigraphy and there is absence of a detectable monoclonal gammapathy. Histological 494 
confirmation and typing of amyloid should be sought in all cases of suspected cardiac 495 
amyloidosis in which these criteria are not met. 496 
In summary, all these imaging techniques are useful and give additional 497 
information, including echocardiography, nuclear techniques, CMR (table 3 (65), but 498 
also EMB and genetic testing, to differentiate ATTR mutant from wild type. Figure 499 
10 illustrates the value of multimodality imaging in a patient with cardiac 500 
amyloidosis.  501 
 502 
 503 
 504 
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3 – Other causes of familial/genetic RCM 505 
Hemochromatosis 506 
Iron overload cardiomyopathy (IOC) results from iron accumulation in the myocardium 507 
mainly because of genetic disorders of iron metabolism (primary hemochromatosis) or 508 
multiple transfusions (such as in thalassemia or myelodysplastic syndromes).   509 
In the early stages, myocardial iron overload (MIO) causes diastolic LV dysfunction (66). If 510 
no effective iron chelation is instituted in time, the majority of patients develops LV 511 
dilatation and reduced LV ejection fraction (EF) (dilated phenotype) (67). In a minority of 512 
cases with severe MIO, restrictive LV dysfunction can lead to pulmonary hypertension, right 513 
ventricular dilatation, and right-sided heart failure with preserved LVEF (restrictive 514 
phenotype) (68). 515 
Echocardiography is a useful modality in the follow-up of iron-loaded patients. A 516 
pseudonormalized pattern of transmitral inflow is frequently encountered and may be 517 
unmasked by tissue Doppler (69). LV diastolic dysfunction and reduced EF may both be 518 
masked by an anemia-induced high cardiac output state in hematologic patients. There are 519 
few data relating diastolic function to outcome in hemochromatosis (70).  520 
However, due to the lower accuracy in quantifying biventricular systolic function  and the 521 
lack of parameters able to predict MIO reliably, echocardiography is only the second-line 522 
imaging method after CMR (71, 72).  523 
The method of choice for assessing IOC is CMR, which allows tissue characterization 524 
including quantification of MIO. The paramagnetic effect of iron-loaded myocardium affects 525 
T1, T2 and T2* relaxation times which can be used to calculate MIO. The best validated 526 
method for quantifying MIO is T2* mapping. T2* values correlate closely with hepatic and 527 
myocardial iron content and correlate better with LV dilatation and LV dysfunction than 528 
serum ferritin or liver iron concentration. A T2* value of < 20 ms at 1.5 Tesla, typically 529 
measured in the interventricular septum, is used as a conservative cut-off for segmental 530 
and global heart iron overload and patients with the lowest T2* values have the highest risk 531 
of developing arrhythmia and heart failure. T2* CMR has revolutionized IOC management 532 
with the death rate in patients with Thalassemia falling dramatically in countries where T2* 533 
CMR has been adopted. In the assessment of IOC, the first cardiac T2* assessment should 534 
be performed as early as possible and the effectiveness of iron chelation (73) and reversal of 535 
MIO can be reliably guided by follow up scans (74). A multislice approach can detect the 536 
uneven distribution of MIO, allowing early identification of patients at risk of cardiac 537 
complications (75).  538 
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T2* is dependent on field strength and sensitive to field inhomogeneity. T2 and T1 mapping 539 
techniques offer some advantages over T2* and have been compared with standard methods, 540 
with initial studies showing close correlation with T2*. 541 
In patients where the diagnosis is unclear, a multiparametric CMR approach that evaluates 542 
cardiac function, myocardial fibrosis and edema may allow further clarification of the 543 
underlying mechanisms leading to the LV dysfunction (76).  544 
 545 
In summary, cardiac involvement is frequent in hemochromatosis. CMR is the main 546 
imaging technique for diagnosis and follow-up of cardiac hemochromatosis, 547 
allowing both reliable measurement of LV and RV dimension and function and tissue 548 
characterization including quantification of MIO. 549 
 550 
Fabry cardiomyopathy 551 
Cardiac involvement is very common and is the most frequent cause of death not only in 552 
hemizygote males but also in female heterozygote carriers with α-Gal A deficiency, with a 553 
reduction of life expectancy of approximately 20 and 15 years respectively (77). The heart 554 
may be the only organ affected in the classic phenotype of Fabry disease, and this is 555 
designated the “cardiac variant” (78). 556 
Cardiovascular manifestations include renovascular and systemic hypertension, aortic root 557 
dilatation, mitral prolapse and congestive heart failure (79). Fabry cardiomyopathy mainly 558 
consists of progressive LVH, which may cause substantial morbidity and contribute to the 559 
reduced life expectancy of affected patients, both male and female (80, 81). 560 
LVH is a hallmark of Fabry cardiomyopathy (82). In patient populations with HCM, the 561 
prevalence of Fabry disease ranges from 0 to 12%, depending on the patient selection criteria 562 
used, but is close to 1% in the largest series (83). LVH is generally symmetrical, although 563 
asymmetric septal hypertrophy has been described, and the condition can mimic the 564 
phenotypical and clinical features of HCM, including obstructive HCM (84). Typically, the 565 
echocardiogram shows marked increases in wall thickness and ventricular dilatation later 566 
in the disease process. Valve leaflet thickening can be seen, and this produces valve 567 
impairment that usually does not require surgical treatment (85). 568 
Echocardiography using TDI can detect the first signs of myocardial damage in a patient 569 
with Fabry cardiomyopathy and normal cardiac wall thickness (86). Furthermore, TDI 570 
studies have been shown to be useful in detecting cardiac involvement in female carriers 571 
with no systemic manifestations of Fabry disease. A reduction of TDI velocities may 572 
represent the first sign of initial intrinsic myocardial impairment (87). These reduced TDI 573 
velocities in mutation positives without LVH are consistent with the hypothesis that 574 
myocardial dysfunction precedes LVH (88). 575 
CMR with LGE may be useful in the non-invasive recognition of myocardial fibrosis, in the 576 
context of cardiac involvement of Fabry disease (89). The LGE pattern of distribution helps 577 
in the differentiation between HCM and Fabry cardiomyopathy (90). Patients with Fabry 578 
cardiomyopathy typically present with a pattern characterized by the involvement of the 579 
inferolateral basal or mid basal segments (89). Furthermore, the myocardial T2 relaxation 580 
time is prolonged in patients with Fabry disease compared with that in HCM patients, and 581 
its measurement could be complementary to the LGE technique. More recently, native T1 582 
mapping was shown to be the most reliable technique to differentiate Fabry cardiomyopathy 583 
from all the other LVH phenocopies, by demonstrating a low native T1 value of the affected 584 
myocardium (whilst other LGE area of different disease would display a high native T1 585 
values) (90). This important difference is due to the characteristic fatty nature of the 586 
infiltration in Fabry disease. 587 
Finally, for most males with Fabry disease, the diagnosis can be made by measuring 588 
leucocyte and plasma α-Gal activity, while genetic testing is useful in patients with normal 589 
levels of enzyme activity (90). A familial screening should be performed in patients with 590 
Fabry’s disease (figure 11). 591 
 592 
In summary, cardiac involvement is frequent in Fabry disease and is associated with 593 
worse outcome. Imaging techniques, especially TDI and CMR, allow a comprehensive 594 
evaluation of cardiac involvement, even before morphological manifestations such 595 
as hypertrophy develop. 596 
 597 
Glycogen storage disease 598 
Glycogen storage disease is defined as the absence or deficiency of one of the enzymes 599 
responsible for making or breaking down glycogen in the body. The enzyme deficiency 600 
causes either abnormal tissue concentrations of glycogen or incorrectly or abnormally 601 
formed glycogen (91, 92). There are 11 different types of glycogen storage diseases causing 602 
different forms of heart failure. Most well-known are Danon and Pompe diseases (82, 93, 603 
94). 604 
Danon cardiomyopathy is progressive and typically manifests a hypertrophic phenotype, 605 
with preserved LVEF and normal cavity dimensions early in the course of disease, and later 606 
progression to dilated features in 11% to 12% of men (92). Hypertrophic cardiomyopathy is 607 
predominant in male patients, whereas an equal prevalence of hypertrophic and dilated 608 
cardiomyopathy is seen in female patients (93).  609 
Echocardiography demonstrates increased LV mass and wall thickness although LV systolic 610 
function is preserved. Taking into consideration the possible progress to cardiac failure, 611 
serial echocardiograms with attention to LV thickness and mass are important in the care 612 
of these patients (94, 95). Echocardiography is also the standard method to evaluate the 613 
cardiac response to enzyme replacement therapy.  614 
Typical findings in CMR consist of significantly reduced LV global function and increase of 615 
LV end-diastolic and end-systolic volumes. Perfusion defects, mainly subendocardial, are 616 
visible in almost all segments on rest first-pass perfusion images. They may be obvious in 617 
the infero-septal segments and partly transmural in the lateral and anterior walls. LGE 618 
appears to be a rare finding in Pompe disease but when present, is seen in the 619 
subendocardium and in places transmurally in the anterior and lateral walls (96, 97).  620 
A diagnosis of Danon disease is always confirmed by EMB results.  621 
99mTc-methoxyisobutylisonitrile (MIBI) myocardial imaging has also been employed as an 622 
imaging diagnostic test for glycogen storage disease, to detect myocardial damage as a non-623 
invasive method. There has been a positive rate of detection of damage with G-MPI of 77.8 624 
% (98). 625 
Other storage / infiltrative diseases (Gaucher disease, mucopolysaccharidoses) may be 626 
rarely associated with cardiac involvement (99, 100). 627 
 628 
 629 
Pseudoxanthoma elasticum 630 
Pseudoxanthoma elasticum is a rare, inherited connective tissue disorder associated with 631 
coronary and peripheral arterial disease and accelerated atherosclerosis in medium sized 632 
arteries (101). Cardiac involvement may start as a diffuse arteriopathy secondary to elastic 633 
fiber dysgenesis, involving the small intramural coronary vessels ('small-vessel disease') and 634 
it may reach the clinical presentation of congestive heart failure, even though – quite often 635 
- with normal epicardial vessels (102). 636 
Echocardiography detects impaired LV systolic and diastolic function (103). Other imaging 637 
modalities – as functional tests – such as perfusion CMR or nuclear myocardial perfusion 638 
imaging, may be useful to demonstrate early coronary involvement and/or the direct 639 
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consequences of ultrastructural defects of the elastic tissue of the heart. Increased 640 
awareness for silent ischemia is recommended (101, 104). 641 
An important study with arterial stiffness evaluation demonstrates the early detection of 642 
accelerated atherosclerosis and the impairment of the elastic properties of the aorta. A lower 643 
elasticity in large arteries, a higher cardiac output and a higher total vascular impedance 644 
were observed in patients with pseudoxanthoma elasticum with respect to the control group 645 
(104). 646 
 647 
 648 
4 - Non familial/non-genetic RCM: Inflammatory cardiomyopathies 649 
with a restrictive hemodynamic component:  650 
Cardiac Sarcoidosis 651 
Sarcoidosis is a multisystem inflammatory granulomatous disease of unknown origin. 652 
Cardiac sarcoidosis (CS) is frequently isolated (105). Its diagnosis is difficult and has 653 
benefited from the use of multimodality imaging. 654 
Although echocardiography is not the method of choice for the diagnosis of cardiac 655 
sarcoidosis, it can offer very useful information in some cases (106). An unexplained reduced 656 
LV ejection fraction <40% in a patient with a histological diagnosis of extra-cardiac 657 
sarcoidosis is suggestive of cardiac sarcoidosis (107). Characteristic echocardiographic 658 
changes suggestive of cardiac sarcoidosis are: wall thickness >13 mm (due to 659 
granulomatous expansion), or <7 mm (due to fibrosis), aneurysmal dilatation especially at 660 
the level of the inferior and posterior walls (108), regional wall motion abnormalities without 661 
any specific coronary distribution, interspersed with normokinetic segments (109). 662 
CMR is one of the imaging modalities recommended for the diagnosis of cardiac sarcoidosis 663 
in current guidelines (106) and CMR may be more sensitive for cardiac involvement than 664 
currently used clinical criteria (110). Myocardial inflammation may be identified by T2 STIR 665 
images and early contrast enhancement while areas of fibrosis are detected by LGE (111) 666 
(figure 12). The typical pattern of cardiac sarcoidosis on LGE is patchy focal enhancement 667 
sparing the endocardial border, not following a coronary artery distribution (112), and 668 
involving mainly the basal and lateral LV walls (113). Single or often multiple lesions are 669 
seen and other, more atypical LGE patterns have also been described. Importantly, no LGE 670 
pattern is pathognomonic for CS. Moreover, CMR offers prognostic information: myocardial 671 
scar determined by LGE is a predictor for ventricular arrhythmia and sudden cardiac death 672 
in patients with sarcoidosis (114).  673 
Nuclear imaging has also an important role in the assessment of cardiac sarcoidosis. 674 
Although the major diagnostic criteria for CS include [67Ga]-citrate scintigraphy, its 675 
sensitivity for CS is significantly lower than [18F]FDG-PET/CT (115). For this reason 676 
[18F]FDG-PET/CT have currently replaced [67Ga]-scintigraphy in the majority of centers 677 
being nowadays the most commonly used imaging test for detecting myocardial 678 
inflammation. Advantages of [18F]FDG-PET/CT over [67Ga], includes favorable tracer 679 
kinetics, lower radiation exposure, and better quality images (116). Active sarcoid lesions 680 
present increased [18F]FDG uptake on PET/CT imaging due to utilization of glucose as an 681 
energy source by inflammatory cell in infiltrates (117). However, [18F]FDG-PET/CT has not 682 
been officially adopted in the diagnostic guidelines (118) mainly due to the high variability 683 
of [18F]FDG uptake in the normal myocardium, that requires adequate patient preparation 684 
to prevent errors. Strategies for myocardial suppression to maximize the accuracy of the 685 
procedure include prolonged fasting, dietary modifications, and a heparin load before 686 
imaging (119). The imaging protocol include preferable gated cardiac [18F]FDG and whole 687 
body images (120). A cardiac perfusion scan could be combined to compare [18F]FDG-PET 688 
and perfusion patterns (Table 4) (121).  689 
Pitfalls in [18F]FDG PET/CT imaging are myocarditis, cardiac amyloidosis, infection, and 690 
myocardial metastases, causing focal [18F]FDG uptake. There are very few circumstances 691 
under which [18F]FDG will be falsely negative as in case of corticosteroids treatment or “old, 692 
non-active” sarcoidosis.  693 
 [18F]FDG-PET/CT sensitivity and specificity for CS have been reported at 89% and 78%, 694 
respectively (117). Quantitative analysis further improved these figures, reaching a 695 
sensitivity of 97.3% and a specificity of 83.6% for the diagnosis of CS. In addition, 696 
standardized uptake value (SUVmax) on [18F]FDG-PET/CT was found the only independent 697 
predictor among clinical and imaging variables for diagnosing CS (122) .  698 
Serial [18F]FDG-PET/CT imaging can be utilized to assess the response to therapies. 699 
Decrease [18F]FDG uptake in cardiac lesions following therapy has been reported in case of 700 
corticosteroid treatment  as well as immunosuppressive therapies (123, 124). Figure 13 701 
illustrates the value of serial [18F]FDG PET/CT in a patient with CS treated with high dose 702 
corticosteroids.  703 
[18F]FDG-PET/CT only moderately correlated with CMR, mainly due to the different 704 
significance of findings: LGE by CMR represents cardiac damage and scarring whereas 705 
[18F]FDG uptake represents active inflammation. When CMR and [18F]FDG -PET/CT were 706 
compared with the Japanese Ministry of Health and Welfare guidelines (JMHWG), CMR had 707 
a higher specificity with lower sensitivity than nuclear imaging (125) .  708 
 709 
In summary, [18F]FDG-PET/CT and CMR are powerful imaging techniques for accurate 710 
detection and therapy monitoring of CS. Protocols for imaging with these modalities 711 
are increasingly well defined, however large prospective studies supporting new 712 
guidelines for CS imaging are warranted.   713 
 714 
Systemic sclerosis 715 
Systemic sclerosis (SSc) is a connective tissue disease characterized by vascular and fibrotic 716 
lesions of skin and internal organs and represents a model of progressive interstitial 717 
myocardial fibrosis triggered by increased endothelin production and also focal 718 
hypoperfusion (126). Cardiovascular involvement has been shown to be one of the leading 719 
causes of mortality in SSc and can occur in up to 70% of patients as a finding on autopsy 720 
(127, 128). Although the primary myocardial involvement remains clinically silent in the 721 
majority of patients, it can lead to further diastolic and systolic LV dysfunction (129), which 722 
carries a poor prognosis. Early diagnosis and accurate staging of myocardial involvement 723 
are therefore crucial for the management of these patients and for therapeutic strategies. 724 
Conventional echocardiographic assessment of the LVEF has shown limited sensitivity being 725 
able to identify only 5% of patients with cardiac involvement (130). Results of studies using 726 
TDI and speckle-tracking echocardiography suggested that myocardial velocity and strain 727 
might be more sensitive than conventional measures in identifying subtle cardiac 728 
dysfunction in asymptomatic patients with SSc (131, 132).  729 
Since myocardial fibrosis is the primary abnormality underlying SSc cardiac involvement, 730 
methods that enable early identification of fibrosis should be preferred. Endomyocardial 731 
biopsy is the gold standard for the detection of myocarditis that may be found in SSc 732 
patients and might help to detect cardiac involvement at an early stage of the disease as 733 
inflammation was found in 96 % and fibrosis in 100% of all SSc patients investigated (133). 734 
Importantly, prognosis was poor and associated with the degree of cardiac inflammation 735 
and fibrosis revealing an event rate of 28% within 22.5 months follow-up (133). 736 
CMR with LGE imaging has been used to detect myocardial areas with replacement fibrosis 737 
in patients with an advanced stage of SSc (134). However, at an early stage of the disease, 738 
myocardial fibrosis in SSc is usually diffuse and thus, undetected by LGE-CMR. ECV 739 
estimation using pre and post contrast T1 mapping has been used to visualize  increased 740 
collagen content in SSc (135). A recent study has demonstrated that ECV imaging performed 741 
early during SS reveals myocardial abnormalities consistent with diffuse myocardial fibrosis 742 
that are not apparent on LGE imaging, therefore representing an early marker of disease. 743 
(136). In addition, the ECV abnormalities correlated with diastolic LV dysfunction which 744 
occurred in 45% of the patients (137). This study also evaluated the systolic circumferential 745 
strain by CMR that was also found decreased but without any correlation with ECV increase, 746 
suggesting therefore that LV systolic dysfunction may be related not only to myocardial 747 
fibrosis but also to other phenomena, such as myocardial ischemia. 748 
In SSc, myocardial ischemia, unrelated to coronary artery disease, is common with 749 
impairment of microcirculation and coronary vasospasm (138). Therefore, stress 750 
echocardiography, CMR stress perfusion and single-photon emission computed tomography 751 
(SPECT) have been proposed to evaluate myocardial perfusion in SS patients 752 
 753 
 754 
5 - Non familial/non genetic RCM: Radiation therapy and cancer 755 
drug therapy induced RCM:  756 
Cardiac toxicity of radiation therapy 757 
In general, the development of radiotherapy-induced RCM suggests a prior high dose chest 758 
irradiation (>60 Gy). It can also occur at lower radiation exposure when anthracycline is 759 
used (139). RCM occurs as a result of diffuse myocardial fibrosis. On echocardiography, the 760 
classical features of RCM are found. Although its value in radiation-related myocardial 761 
fibrosis is still unclear, ECV estimation using pre and post contract T1 mapping by CMR is 762 
directly related to collagen content (140). The presence of decreased mean LV mass, end-763 
diastolic dimension, and end-diastolic wall thickness together with dilation of both atria and 764 
self-reported dyspnea, is suggestive of RCM in this population (141). Cardiac CT has little 765 
value in the diagnosis of RCM after radiotherapy, except for the detection of any associated 766 
vascular disease. There is no proven value of nuclear cardiology in the detection of RCM 767 
after radiation exposure. However, perfusion scintigraphy imaging can reveal fixed regional 768 
perfusion defects, which possibly indicate direct damage and the presence of local fibrosis 769 
(142). 770 
 771 
 772 
Cancer drug induced RCM 773 
The typical structural manifestation of cancer drug induced cardiomyopathy corresponds 774 
to a LV eccentric remodeling with dilation of internal cavity and thinning of myocardial walls 775 
[143]. When clinical heart failure is overt, this picture is associated with a significant 776 
reduction of LV ejection fraction. In the more advanced stages LV diastolic function can be 777 
strongly altered, with an abnormal increase of LV filling pressure. This will induce the 778 
classic "restrictive" physiology with the typical standard Doppler-derived transmitral 779 
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pattern: E/A ratio > 2 or even > 3 and short E velocity deceleration time (usually < 150-160 780 
msec). The presence of a restrictive pattern in a patient with cancer drug induced 781 
cardiotoxicity has a recognized prognostic value, exactly as this occurs in the general clinical 782 
setting [8].     783 
Currently, the restrictive diastolic pattern is detectable in particular in patients undergoing 784 
anthracyclines (Cardiotoxicity type 1), it being possibly evident not only during treatment 785 
(acute cardiotoxicity) but also - and more often - after the completion (even several years 786 
after) of cancer therapies [143]. (figure 14, videos 6 and 7). Early cardiotoxicity, occurring 787 
during or within 1 year of completion of treatment, is the most important risk factor for the 788 
development of late cardiotoxicity, which occurs beyond a year of completion of treatment. 789 
This is very important to know in children undergoing anthracyclines therapy. In fact, they 790 
can develop late cardiotoxicity during adulthood and should be therefore carefully 791 
monitored for years by echocardiography. Cumulative as well as peak anthracycline doses 792 
affect adults and children alike. 793 
The restrictive physiology of diastolic pattern is instead very rare in patients undergoing 794 
trastuzumab therapy and similar drugs (Cardiotoxicity type 2) [143]. This kind of 795 
cardiotoxicity is usually reversible with cancer therapy interruption. However, since 796 
trastuzumab can be sequentially added to anthracyclines, a combined effect anthracyclines 797 
+ trastuzumab on the degree of LV filling pressures cannot be excluded and should therefore 798 
be carefully monitored. 799 
When a restrictive LV diastolic pattern is detectable in patients receiving cancer drugs, the 800 
echocardiographic exam should be extended to a quantitative evaluation of LV longitudinal 801 
function. In fact, when high levels of LV filling pressure are evident, a reduction of global 802 
longitudinal strain (GLS), measurable by speckle tracking echocardiography, is usually 803 
observed. If speckle tracking echocardiography is not available, pulsed tissue Doppler 804 
derived s' velocity of the mitral annulus or even the simple M-mode derived mitral annular 805 
plane systolic excursion represent much more than simple surrogates of LV longitudinal 806 
dysfunction.      807 
In this cohort of patients, CMR can be useful both for the accurate volumetric assessment 808 
with cine imaging but also with the LGE technique for the detection of myocardial fibrosis 809 
[143], i.e., the first determinant of LV diastolic dysfunction and LV filling pressure increase. 810 
 811 
 812 
 813 
 814 
 815 
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6 – Endomyocardial RCMs  816 
Endomyocardial fibrosis 817 
Endomyocardial fibrosis (EMF) is an often-neglected disorder in the tropical and subtropical 818 
regions of the world which is characterized by the development of a restrictive 819 
cardiomyopathy (144), and is associated with a high morbidity and mortality (145). As 820 
etiologic causes of endomyocardial fibrosis, infections, inflammation, allergy, malnutrition 821 
and toxic agents are discussed (146).  At the histological level, EMF is characterized by a 822 
marked endocardial thickening due to the deposition of fibrous tissue (Figure 15)(147).  823 
An echocardiographic examination of 1063 individuals revealed that most subjects (55%) 824 
had a biventricular involvement, and 28% revealed a right-sided prevalence with mild-825 
moderate structural and functional echocardiographic abnormalities (148). 826 
Regarding the diagnosis of EMF, transthoracic echocardiographic changes can be useful for 827 
visualizing structural abnormalities, especially in chronic EMF (145, 147). The main 828 
echocardiographic features include apical obliteration of the left and / or right ventricles, 829 
reduced volume of the ventricular cavity, endocardial thickening and a restrictive pattern. 830 
(figure 16, video 8) 831 
Endomyocardial fibrosis may be difficult to differentiate from other cardiomyopathies 832 
(Loeffler´s endocarditis, Churg-Strauss syndrome or rheumatoid arthritis, tuberculous 833 
pericarditis, constrictive pericarditis or apical HCM (145, 149-151). After initial 834 
echocardiographic analysis, CMR (152) including LGE imaging  should be performed which 835 
is now the gold standard for imaging the disease.(figure 17)  In a CMR study of 36 patients 836 
it was shown that LGE-CMR can provide detailed information on ventricular morphology, 837 
including the existence of thrombus or calcifications, and revealing functional information 838 
which is useful in the diagnosis and prognosis of EMF through quantification of the typical 839 
pattern of the endocardial fibrous tissue deposition (153). Adjunctive diagnostic tools, such 840 
as EMB, can be considered in ambiguous cases (154) and can help in patient management. 841 
 842 
 843 
Hypereosinophilic syndrome 844 
Eosinophilic endomyocardial fibrosis is a rare cause of RCM, resulting from toxicity of 845 
eosinophils towards cardiac tissues (155).  The causes for eosinophilic infiltration of 846 
myocardium are hypersensitivity, parasitic infestation, systemic disease, myeloproliferative 847 
syndrome and idiopathic hypereosinophilic syndrome (155).  848 
Cardiac disease follows three stages, with involvement of the endocardium, the myocardium 849 
and the pericardium. The first is eosinophilic myocarditis (acute necrotic stage) due to 850 
infiltration of eosinophils and release of the contents of their granules in the myocardium 851 
(155). There is no relationship between the extent of the infiltrate and clinical symptoms 852 
(156). The intermediate phase is the thrombotic stage, characterized by mural thrombi along 853 
the damaged endocardium (more often in the apex of the left ventricle). The third stage is 854 
the later fibrotic stage in which the granulation tissue is changed into hyaline fibrosis. The 855 
endocardial scar can results in a decrease of ventricular compliance and in RCM (157). 856 
On echocardiography, classical findings are progressive endomyocardial thickening, apical 857 
obliteration of one or both ventricles by echogenic material suggestive of fibrosis or 858 
thrombus formation, posterior mitral leaflet involvement and papillary dysfunction resulting 859 
in mitral regurgitation (157, 158) (figure 18a). Pericardial effusion can be present as well as 860 
the typical RCM pattern of normal-to-small ventricles with large atria (159). 861 
Echocardiography can also be useful for monitoring the effects of specific therapies on the 862 
reversal of endomyocardial infiltration in hypereosinophilic cardiomyopathy (160). 863 
CMR is very useful in endomyocardial fibrosis, both for diagnosis of endocardial involvement 864 
and for detection of thrombus formation in both ventricles (161-164)(figure 18b). The gold 865 
standard is EMB but the high resolution of CMR and TTE is frequently sufficient for 866 
diagnosis and follow-up. (3).  867 
 868 
 869 
Carcinoid heart disease 870 
Carcinoid heart disease occurs in 20% to 70% of patients with metastatic carcinoid tumors 871 
and will lead to increased morbidity and mortality in these patients. (165)  The endocardial 872 
fibrosis results in retraction and fixation of the heart valves. Right-sided valves are mainly 873 
affected(166). Left-sided valvular pathology occurs in approximately 10% of patients with 874 
carcinoid heart disease and is associated with right-to-left shunting, bronchial carcinoid, or 875 
poorly controlled carcinoid syndrome. (167, 168). 876 
The hallmarks of carcinoid heart disease are a combination of right-sided valvular 877 
dysfunction and typical morphological changes of the valves like valve leaflet thickening, 878 
shortening, retraction, reduced mobility, or incomplete coaptation of the tricuspid leaflets. 879 
(169- 171). CMR has an additive value in carcinoid heart diseases, especially when 880 
echocardiography is inconclusive and for accurate measurements of right ventricular 881 
function and assessment of carcinoid plaques using LGE (171). Figure 19, videos 9 and 10, 882 
illustrate the value of multimodality imaging in a patient with carcinoid heart disease. 883 
 884 
 885 
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Drug-induced endomyocardial fibrosis 886 
Animal data suggest the possibility of drug-induced endomyocardial fibrosis induced by 5-887 
HT2B serotonin receptor agonists such as fenfluramine derivatives, pergolide, cabergolide 888 
and methysergid and ergotamine (172-174), but very scarce data are currently reported in 889 
man. Indeed, only one case of RCM is reported after fenfluramine-phentermine exposure 890 
(175). In addition, a case of sub-aortic obstruction within the LV outflow tract related to 891 
drug-induced endomyocardial fibrosis has been recently reported in a patient exposed to 892 
benfluorex, an agonist of 5-HT2B serotoninergic receptors (176).  893 
 894 
 895 
6. Differential diagnosis between RCM and other cardiac diseases 896 
Differential diagnosis between RCM and constrictive pericarditis 897 
Differential diagnosis between RCM and constrictive pericarditis (CP) can be a challenge as 898 
their clinical presentation is relatively similar with right heart failure symptoms, preserved 899 
LV ejection fraction, and diastolic dysfunction. However, as the treatment of these two 900 
conditions is very different, constriction being potentially curable by surgery, making the 901 
correct diagnosis is critically important. The differential diagnosis could be performed 902 
particularly using the complementary elements obtained from TTE, CMR, cardiac CT, or 903 
cardiac catheterization. (table 5) 904 
Cardiac catheterization was the first method historically used to help in the differential 905 
diagnosis of RCM and CP, but is not always conclusive (177, 178). 906 
In both RCM and CP, biatrial dilatation, venous dilatation as well as pericardial effusion can 907 
be observed. Several echocardiographic parameters have been identified to differentiate 908 
myocardial diseases from pericardial constriction (10, 179). In case of RCM, some degree of 909 
LV or biventricular hypertrophy or unusual echo texture can be noted (RCM of infiltrative 910 
origin). In case of constrictive pericarditis, pericardial thickening (>3mm) or 911 
hyperechogenicity of the pericardium can be observed. But one of the main characteristics 912 
of CP is the absence of transmission of the intrathoracic pressure variations to the heart, 913 
which are physiologically present during the respiratory cycle.  914 
Both TTE and real time cine CMR allow the identification of some key findings which 915 
differentiate the two pathologies: septal bulging occurring with cavity volume variations and 916 
the exaggerated respiratory-related LV-RV coupling highlighted by a respiratory septal shift 917 
observed in CP and a significant respiratory variation of the diastolic flow. The respiratory 918 
septal shift is defined by a difference in the maximal septal excursion into LV between 919 
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inspiration and expiration (Video 11).(179) Using CMR, this parameter has a sensitivity of 920 
80% and specificity of 100% to detect CP. (180)  921 
Other echocardiographic findings have been reported to be useful for differentiating RCM 922 
and CP, including TDI (e’), E velocity deceleration time, pulmonary vein flow, left atrial 923 
volume, and E/e’ ratio (181). Figure 20 shows an algorithm proposed by the recent ASE / 924 
EACVI recommendations for the evaluation of diastolic function by echocardiography (8), 925 
comparing constrictive pericarditis and RCM. The presence of a normal annular e’ velocity 926 
in a patient referred with heart failure diagnosis should raise suspicion of pericardial 927 
constriction (8). 928 
LV myocardial velocities (182-185) and deformation (11) measured by both TTE and CMR 929 
(186) are reduced at a greater degree in RCM compared to constrictive pericarditis. Both 930 
echocardiography and CMR provide concordant diagnostic information and incremental 931 
value for differentiating constrictive pericarditis from RCM. Complementary assessment of 932 
structural (pericardial thickening), mechanical (myocardial velocities and strains) and 933 
hemodynamic (respiratory septal shift) by both TTE and CMR and their complementary use 934 
increase the cost-efficacy and confidence for the diagnosis of RCM vs. constrictive 935 
pericarditis.  936 
Cardiac CT provides excellent anatomic delineation of the pericardium, allowing for accurate 937 
measurement of pericardial thickness (abnormal if >4mm) (187), although a normal 938 
pericardial thickness does not exclude constrictive pericarditis (188). Cardiac CT is superior 939 
to CMR in detecting pericardial calcifications (189). Finally, multimodality imaging should 940 
be performed in patients with suspected constrictive pericarditis, since each imaging 941 
modality presents with both advantages and limitations (table 5, figure 21)  942 
 943 
In summary, the differentiation between RCM and constrictive pericarditis is 944 
frequently difficult and should take into account both clinical presentation and 945 
multimodality imaging. The absence of pericardial thickening does not rule out 946 
constrictive pericarditis.  Echocardiography, CMR and CT provide complementary 947 
information and in many patients all three should be performed when constrictive 948 
pericarditis is suspected. 949 
 950 
 951 
Differential diagnosis or association between RCM and other 952 
myocardial diseases 953 
Although in its most typical « apparently idiopathic » form, RCM presents without LV 954 
hypertrophy, in some patients, some forms of cardiomyopathy may resemble or be 955 
associated with RCM. Particularly, HCM may resemble RCM in some patients. The classical 956 
HCM phenotype presents with enhanced contractility, small cavity, reduced indexed stoke 957 
volume, LVOT obstruction, grade 1 diastolic dysfunction with some fibrosis (190, 191). As 958 
the disease progresses, extensive fibrosis (52), reduced systolic function (52), diastolic 959 
dysfunction (192, 193), marked dilatation of the atria (194), relative thinning of the LV walls, 960 
loss of LVOT obstruction (194-196) and pulmonary hypertension (196) dominate the picture, 961 
mimicking RCM.         962 
Isolated LV non-compaction is a rare form of cardiomyopathy (197), which should also be 963 
differentiated from RCM, but is also sometimes associated with a restrictive pattern or even 964 
a true RCM (198) (figure 22, video 12) 965 
  966 
 967 
7. Conclusion and future directions 968 
RCM represents a heterogeneous group of cardiac diseases, with different 969 
pathophysiological processes, clinical presentation, treatment, and prognosis. The two main 970 
objectives of the clinician are to rule out constrictive pericarditis, and to find a potentially 971 
treatable cause of RCM. Imaging techniques including echocardiography, cardiac CT, CMR, 972 
and nuclear techniques are of utmost value for the diagnostic and prognostic assessment 973 
of RCM. These techniques give additional information and should frequently be used in 974 
combination in the same patient to maximize diagnostic performance. Finally, additional 975 
investigations such as endomyocardial biopsy, familial screening, and genetic studies are 976 
frequently necessary in these patients. For these reasons, patients with suspected RCM 977 
should be referred to specialized centers that can provide multimodality imaging and a 978 
multidisciplinary team approach.  979 
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Figure legends: 986 
 987 
Figure 1: ASE – EACVI criteria for grading LV diastolic function in patients with depressed LVEF and 988 
patients with myocardial disease and normal LVEF after consideration of clinical and other 2D data. 989 
(from reference 8 with permission) 990 
 991 
Figure 2: 74 year old patient presenting with breathlessness. Cine CMR showed global left ventricular 992 
hypertrophy, impaired longitudinal LV shortening and dilated atria. Late gadolinium enhanced CMR 993 
in the figure showed diffuse endocardial enhancement consistent with infiltrative disease. 994 
Subsequently the patient was found to have amyloidosis.  LV: left ventricle; RV: right ventricle; LA: 995 
left atrium; RA: right atrium 996 
 997 
Figure 3: Patient With Acute Myocardial Sarcoidosis (from reference 37 with permission) 998 
Patient (62-year-old male) followed for histologically proven pulmonary sarcoidosis treated by steroids 999 
for 10 years presented with symptoms of acute breathlessness. Cardiac involvement was suspected. 1000 
LGE-CMR (A) images showed patchy LGE of the lateral wall. Matched FDG-PET (B) and fused FDG-1001 
PET/MR (C and D) images obtained in short-axis view showed intense uptake in exactly the same 1002 
territory as the pattern of injury on CMR (maximum standardized uptake value of LGE territory/blood 1003 
pool uptake ratio = 2.7). A 2-chamber cine CMR (E) sequence showed mild hypokinesis of the lateral 1004 
wall and mild overall left ventricular systolic impairment (left ventricular ejection fraction = 52%). 1005 
Maximum intensity projection FDG-PET (F) cine view confirmed abnormal myocardial uptake without 1006 
evidence of increased activity outside of the heart.  1007 
 1008 
Figure 4: Imaging of RCM at the cellular level. Different disease entities of RCM are visualized by 1009 
histology and immunohistology. Sarcoidosis with typical granulomas, fibrosis (blue tissue) (A, 1010 
Masson trichrome stain) and numerous CD68+ macrophages and giant cells (B, 1011 
immunohistochemistry). Hypereosinophilic syndrome with myocyte necrosis, eosinophilic 1012 
granulocytes (C, Giemsa stain) and CD68+macrophages (D, immunohistochemistry). Storage 1013 
diseases: Hemochromatosis with iron containing myocytes (E, Prussian blue), and fibrosis (F, Sirius 1014 
red). AL-amyloidosis (G, AL-amyloid immunohistochemistry (green), H, Kongo red). Glycogenosis with 1015 
hypertrophic, vacuolated myocytes and fibrosis (I, Masson trichrome stain) and large amounts of 1016 
glycogen (J, PAS stain (red)). (A,B x 100x, C-J x200). 1017 
  1018 
 1019 
Figure 5: echo findings in 3 patients with apparently idiopathic RCM.  1020 
5a and video 1(TTE), 5b (CMR): impressive dilatation of both atria predominating on the right 1021 
cavities, contrasting with small LV and RV cavities 1022 
5c and video 2: more classical form of idiopathic RCM with normal ventricular systolic function and 1023 
severe atrial dilatation 1024 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium 1025 
5d: Multimodality imaging in a severe RCM. Patient in atrial fibrillation, and a pace maker for 1026 
severe atrio-ventricular block.  Huge atria that can be seen on the CT (1), the chest X-ray (2) and 1027 
the Echocardiography (6). There is a severe tricuspid regurgitation (5) and a severe alteration of the 1028 
longitudinal systolic and diastolic function as shown by the tissue Doppler (5),and the strain data 1029 
(4). Extensive circumferential subendocardial late gadolinium enhancement is observed by CMR (3). 1030 
 1031 
Figure 6a- 2D echocardiography in a 52 year-old male with cardiac amyloidosis, AL type, associated 1032 
with plasma cell dyscrasia: non- dilated LV with moderate concentric LVH with ‘granular sparkling’ 1033 
appearance, mitral valve thickening, mild to moderate  biatrial dilatation, inter atrial septum 1034 
infiltration (loss of physiological echo drop-out) and mild pericardial effusion 1035 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium, Ao: aorta 1036 
Figure 6b- Diastolic function in the same patient: E/A >>1 (PWD transmitral inflow), low systolic 1037 
and diastolic myocardial velocities (TDI), E/e’ =25, reflecting high LV filling pressures 1038 
 1039 
Figure 7a- 2D-STE apical longitudinal view in systemic AL amyloidosis : severely abnormal 1040 
longitudinal strain,  particularly in the  basal and medial LV segments 1041 
Figure 7b- Systemic AL amyloidosis , multiple myeloma: 2D-STE : Relative apical sparing, typical of 1042 
cardiac amyloidosis. Note the abnormal GLS ( -4,9%) 1043 
 1044 
Figure 8a. CMR in a 79-year old patient with cardiac amyloidosis showing mild septal hypertrophy 1045 
(16mm), biatrial enlargement, and diffuse patchy uptake of gadolinium throughout the 1046 
midventricular and basal segments of the septal, anterior and inferior wall with sparing of the 1047 
apicolateral wall. (Note small areas of bilateral subendocardial LGE in the septal wall characteristic 1048 
of cardiac amyloidosis (arrows) and LGE in the right ventricular free wall and the left atrium). 1049 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium 1050 
 1051 
Figure 8b. Late-phase planar 99mTc-DPD-scintigraphy (anterior views) in a patient with ATTR 1052 
amyloidosis (A) and a normal control (B). Note intense cardiac uptake in (A) demonstrating cardiac 1053 
amyloidosis. Moreover, increased soft tissue uptake particularly in the shoulder region and the 1054 
abdominal wall with obscuring of bone uptake can be observed as a typical pattern of ATTR 1055 
amyloidosis. 1056 
 1057 
Figure 9: Diagnostic algorithm for patients with suspected amyloid cardiomyopathy. (from reference 1058 
64 with permission). AApoA1 indicates apolipoprotein A-I; DPD, 3,3-diphosphono-1,2-1059 
propanodicarboxylic acid; HDMP, hydroxymethylene diphosphonate; and PYP, pyrophosphate. 1060 
 1061 
Figure 10: multimodality imaging in a patient with familial TTR amyloidosis 1062 
10a: and video 3: 2D echo long-axis view showing LV hypertrophy and pericardial effusion 1063 
10b: and video 4: apical sparing by 2D strain 1064 
10c: intense cardiac uptake on 99mTc scintigraphy 1065 
10d and video 5: CMR confirming LV hypertrophy and pericardial effusion 1066 
RV: right ventricle, LV: left ventricle, LA: left atrium, Per: pericardial effusion 1067 
 1068 
Figure 11: familial Fabry’s disease in 2 brothers 1069 
- 11a: EKG in a 55 year-old male showing a pattern of apical hypertrophy 1070 
- 11b: apical transthoracic view showing an apical hypertrophy (arrow) 1071 
- 11c: CMR finding of predominantly apical hypertrophy 1072 
- 11d: inferolateral late gadolidium enhancement 1073 
- 11e: EKG in his young brother showing milder but similar abnormalities 1074 
- 11f: concentric diffuse hypertrophy in the brother 1075 
RV: right ventricle, LV: left ventricle, LA: left atrium, RA: right atrium 1076 
 1077 
Figure 12: Patient with known cardiac sarcoidosis. The image shows a late gadolinium enhanced 1078 
CMR image in the vertical long axis plane. Several focal areas of myocardial enhancement can be 1079 
seen (arrows) consistent with granulomatous myocardial infiltration. 1080 
 1081 
Figure 13: 41 year-old male with a total AV-block, bradycardia and weakness. The patient was 1082 
suspected of cardiac sarcoidosis. Echocardiography was normal. A FDG PET/CT was performed after 1083 
careful patient preparation with a fatty diet and showed heterogeneous, spotty high uptake in the 1084 
left ventricle of the heart (left whole body PET and upper row right short axis PET/CT). The patient 1085 
was treated with high dose corticosteroids and the repeated FDG PET/CT after 3 months shows fully 1086 
normalization of the myocardium (right whole body FDG PET/CT and lower short axis PET/CT). 1087 
 1088 
 1089 
 1090 
Figure 14 and videos 6 and 7:25 year-old woman treated for Hodgkin disease in infancy with 1091 
anthracyclins.  1092 
Chest X ray (1) and echocardiography (2 and 3) show a non-dilated left ventricle, with a relatively 1093 
preserved LV contractility (video 6). However, mitral flow (4) and pulmonary venous flow (5) show a 1094 
severely restrictive pattern and tricuspid flow recording (6) reveals pulmonary hypertension. Severe 1095 
longitudinal dysfunction is evidenced by 2D strain (video 7) 1096 
 1097 
 1098 
Figure 15: histologic finding in a patient with endomyocardial fibrosis 1099 
 1100 
 1101 
Figure 16a and video 8 (TTE), 16b (CMR): right ventricular endomyocardial fibrosis in a 50 year-old 1102 
woman. The apex of the right ventricle is obliterated (white arrow), with subsequent surgical 1103 
confirmation. 1104 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium 1105 
 1106 
Figure 17: LV endomyocardial fibrosis in a 58 year-old man presenting with congestive heart failure 1107 
17a: Cine 4 chamber view in end-diastolic phase showing a thickening of LV apex (black arrow), a 1108 
reduced volume of the left ventricular cavity and a left atrial enlargement. 1109 
17b: LGE 4 chambers view showing a marked endocardial thickening with late gadolinium 1110 
enhancement (black arrow) and an apical thrombus (open arrow). 1111 
 1112 
 1113 
Figure 18a: Multimodality imaging in hypereosinophilic syndrome with cardiac involvement showing 1114 
severe restriction of the posterior mitral leaflet associated with involvement of the subvalvular 1115 
apparatus and severe mitral regurgitation by echocardiography (a, b) and CMR (c) with worsening in 1116 
the follow-up (d). From reference 158 with permission 1117 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium 1118 
 1119 
Figure 18b: CMR in a patient with hypereosinophilic syndrome and Loeffler's syndrome. Cine image 1120 
(still frame) (A) demonstrates a dilated left ventricle and moderate pericardial effusion (asterisks). 1121 
T2-weighted image (B,C) shows subendocardial high signal intensity suggestive of inflammation 1122 
(white arrows), and T1-weighted images after contrast administration (D–F) demonstrate 1123 
endocardial fibrosis (arrowheads). Of note, an RV apical thrombus is evident in the cine image and 1124 
in the T1-weighted sequences (triangles) (from reference 162 with permission) 1125 
 1126 
Figure 19, videos 9 and 10: carcinoid disease with right heart involvement. 1127 
19a (TTE) and 19c (CMR):  Restriction of the movements of the tricuspid leaflets, which are 1128 
thickened. The right ventricle myocardium is also involved 1129 
19b: massive tricuspid regurgitation (TTE) 1130 
19c: CMR showing dilatation of right heart cavities and restricted tricuspid leaflet (arrow) 1131 
RA: right atrium, RV: right ventricle, LV: left ventricle, LA: left atrium 1132 
 1133 
Figure 20: ASE / EACVI algorithm comparing constrictive pericarditis and restrictive 1134 
cardiomyopathy.  1135 
 1136 
Figure 21: Multimodality imaging in a patient with constrictive pericarditis  1137 
21a: CMR: Cine 4 chambers view in end-diastolic phase showing a circumferential pericardial 1138 
thickening (black arrows), biatrial dilatation and septal convexity inversion (open arrow) 1139 
21b: Cardiac CT: Axial thoracic CT scan showing a circumferential pericardial thickening (black 1140 
arrows). 1141 
 1142 
Video 11: CMR in constrictive pericarditis, illustrating the respiratory septal shift (difference in the 1143 
maximal septal excursion into LV between inspiration and expiration) 1144 
 1145 
Figure 22 and video 12: left ventricular hypertrabeculation (arrows) in a young patient with severe 1146 
RCM 1147 
 1148 
 1149 
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 1152 
 1153 
 1154 
 1155 
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